BR0110706A - Genes gagpol sintéticos e seus usos - Google Patents

Genes gagpol sintéticos e seus usos

Info

Publication number
BR0110706A
BR0110706A BR0110706-2A BR0110706A BR0110706A BR 0110706 A BR0110706 A BR 0110706A BR 0110706 A BR0110706 A BR 0110706A BR 0110706 A BR0110706 A BR 0110706A
Authority
BR
Brazil
Prior art keywords
gagpol genes
synthetic
genes
synthetic gagpol
generation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
BR0110706-2A
Other languages
English (en)
Inventor
Ralf Wagner
Markus Graf
Ludwig Demil
Kurt Bieler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GENEART AG (DE)
Original Assignee
GENEART GMBH
GENEART GMBH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8168767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0110706(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GENEART GMBH, GENEART GMBH filed Critical GENEART GMBH
Publication of BR0110706A publication Critical patent/BR0110706A/pt
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"GENES GAGPOL SINTéTICOS E SEUS USOS". A presente invenção está relacionada com os genes gagpol e gag otimizados para alto nível de expressão via otimização de códon e os seus usos para a produção eficiente de partículas de vetor. A invenção também está relacionada com a produção de células e vacinas envelopadas com base nos genes gagpol e gag sintéticos.
BR0110706-2A 2000-05-18 2001-05-18 Genes gagpol sintéticos e seus usos Pending BR0110706A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00110623A EP1156112B1 (en) 2000-05-18 2000-05-18 Synthetic gagpol genes and their uses
PCT/EP2001/005744 WO2001088141A2 (en) 2000-05-18 2001-05-18 Synthetic gagpol genes and their uses

Publications (1)

Publication Number Publication Date
BR0110706A true BR0110706A (pt) 2003-01-28

Family

ID=8168767

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110706-2A Pending BR0110706A (pt) 2000-05-18 2001-05-18 Genes gagpol sintéticos e seus usos

Country Status (10)

Country Link
US (3) US7378515B2 (pt)
EP (2) EP1156112B1 (pt)
CN (1) CN1429270A (pt)
AT (2) ATE318908T1 (pt)
AU (1) AU2001281781A1 (pt)
BR (1) BR0110706A (pt)
CA (1) CA2408433A1 (pt)
DE (2) DE60026199T2 (pt)
HK (2) HK1042319B (pt)
WO (1) WO2001088141A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2422882A1 (en) * 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
EP1201750A1 (en) 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
EP1427826B1 (en) * 2001-09-20 2011-04-20 Glaxo Group Limited HIV- RT-nef-Gag codon optimised DNA vaccines
DE10260805A1 (de) * 2002-12-23 2004-07-22 Geneart Gmbh Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins
CA2756797C (en) 2002-12-23 2015-05-05 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
US20050220816A1 (en) * 2004-03-31 2005-10-06 Advanced Bioscience Laboratories, Inc. Mutant viral nucleic acids and vaccine containing same
DE102004037611B4 (de) * 2004-08-03 2013-10-02 Geneart Ag Induzierbare Genexpression
EP1776460B8 (de) 2004-08-03 2014-02-26 Geneart Ag Verfahren zur modulation der genexpression durch änderung des cpg gehalts
ES2281252B1 (es) * 2005-07-27 2009-02-16 Consejo Superior De Investigaciones Cientificas Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
WO2013156443A1 (en) 2012-04-17 2013-10-24 F. Hoffmann-La Roche Ag Method for the expression of polypeptides using modified nucleic acids
JP7511591B2 (ja) 2019-06-28 2024-07-05 エフ． ホフマン－ラ ロシュ アーゲー 抗体の製造方法
WO2021094984A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2280195A1 (en) * 1997-02-07 1998-08-13 Merck & Co., Inc. Synthetic hiv gag genes
WO2000015819A1 (en) * 1998-09-11 2000-03-23 The Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
AU2487300A (en) * 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof

Also Published As

Publication number Publication date
EP1282712B1 (en) 2006-07-19
ATE318908T1 (de) 2006-03-15
CA2408433A1 (en) 2001-11-22
US20070293448A1 (en) 2007-12-20
US8287881B2 (en) 2012-10-16
DE60121572T2 (de) 2007-06-28
US20040152069A1 (en) 2004-08-05
DE60121572D1 (de) 2006-08-31
ATE333503T1 (de) 2006-08-15
DE60026199T2 (de) 2006-11-23
AU2001281781A1 (en) 2001-11-26
EP1282712A2 (en) 2003-02-12
HK1042319B (zh) 2006-10-20
DE60026199D1 (de) 2006-04-27
HK1053853A1 (en) 2003-11-07
WO2001088141A3 (en) 2002-04-18
WO2001088141A2 (en) 2001-11-22
HK1042319A1 (en) 2002-08-09
CN1429270A (zh) 2003-07-09
US7378515B2 (en) 2008-05-27
EP1156112B1 (en) 2006-03-01
EP1156112A1 (en) 2001-11-21
US20130122585A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
BR0110706A (pt) Genes gagpol sintéticos e seus usos
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
HUP0301659A2 (hu) Kukorica cellulóz-szintetázok és alkalmazásuk
IL143326A0 (en) Method of cloning porcine animals
GB2405406B (en) Viral vectors
ATE361366T1 (de) Aus bacillus stammende transglutaminase
YU9403A (sh) Anti-dualna antitela integrina, kompozicije, postupci i primene
MEP44408A (en) Anti-il-12 antibodies, compositions, methods and uses
DK1373301T3 (da) Reducering af immunogeniciteten af fusionsproteiner
TR200001946T2 (tr) Aşı
ATE388237T1 (de) Dendritische zellhybride
DK580583A (da) Derivater af cis,endo-2-azabicyclo-(5.3.0)-decan-3-carboxylsyre, fremgangsmaade til deres fremstilling samt midler indeholdende disse og deres anvendelse
EP1555324A4 (en) DEFRUCTOSYLATION PROCESS
IL143670A0 (en) Methods for the expression of active protein-immunoglobulin fusions, active protein-immunoglobulin fusions obtained thereby and pharmaceutical compositions containing the same
DE60226852D1 (de) Lentivirale verpackungskonstrukte
DE60042816D1 (de) T-helferzellen-epitope
ATE408009T1 (de) Identifizierung und charakterisierung einer anthocyaninmutante (ant1) in tomate
BR9803232A (pt) Vaicna de neospora.
HK1016599A1 (en) Fused isoindolones as inhibitors of protein kinase c
ATE494377T1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden
DE60118456D1 (de) Pestivirus Mutanten und dessen enthaltende Impfstoffe
DE69232858D1 (de) Herpesvirus-partikel zubereitung und vakzine
AU2001240078A1 (en) Highly efficient gene transfer into human repopulating stem cells by rd114 pseudotyped retroviral vector particles
FI925644A0 (fi) Foerfarande foer framstaellning av sulfinylpristinamycin iib
HUP0105230A2 (hu) Specifikus hibrid promóterek alkalmazása szöveti kifejeződés szabályozására

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: GENEART AG (DE)

Free format text: ALTERADO DE: GENEART GMBH

B25G Requested change of headquarter approved

Owner name: GENEART AG (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070142696/RJ DE 10/10/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]